BioStem Technologies EBIT Margin 2024-2025 | BSEM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

BioStem Technologies ebit margin from 2024 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

BioStem Technologies ebit margin from 2024 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$247.1B
Amgen (AMGN)	$155.3B
Gilead Sciences (GILD)	$141.6B
Vertex Pharmaceuticals (VRTX)	$99.7B
Bristol Myers Squibb (BMY)	$96B
GSK (GSK)	$80.7B
CSL (CSLLY)	$67.1B
Regeneron Pharmaceuticals (REGN)	$60.7B
Alnylam Pharmaceuticals (ALNY)	$58.2B
Argenex SE (ARGX)	$41.5B
Insmed (INSM)	$27.1B
BioNTech SE (BNTX)	$25.3B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.6B
Genmab (GNMSF)	$16.2B
Genmab (GMAB)	$15.6B
Illumina (ILMN)	$15.3B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.9B
Exelixis (EXEL)	$10.2B
Moderna (MRNA)	$9.9B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Bio-Techne Corp (TECH)	$8.9B
Exact Sciences (EXAS)	$8.6B
Halozyme Therapeutics (HALO)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.9B